together with our patients, we strive to extend survival in some of the most aggressive forms of cancer
about us
our therapy
our pipeline
careers
news and media
investor relations
NEWS
Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of TTFields Therapy for Pancreatic Cancer
PANOVA-3 met its primary endpoint with a statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma treated in the first line with TTFields concomitant with gemcitabine and nab-paclitaxel.
patient forward
We are a global oncology company striving to extend survival in some of the most aggressive forms of cancer. Learn more about our company and our mission through stories about patients, our colleagues, our collaborators and our culture.